Ser265

Site Information
VEQEDELsDVsQGGs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 482032
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 )
Disease tissue studied:	breast cancer ( 4 , 13 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 19 ) , cervical adenocarcinoma ( 19 ) , lung cancer ( 5 , 6 , 7 , 8 , 13 ) , non-small cell lung cancer ( 5 , 6 , 7 , 8 , 10 , 12 , 13 ) , non-small cell lung adenocarcinoma ( 5 , 6 , 7 , 8 ) , non-small cell large cell lung carcinoma ( 6 , 7 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 18 ) , 293 (epithelial) ( 21 ) , A549 (pulmonary) ( 5 ) , breast ( 1 ) , BT-549 (breast cell) ( 13 ) , Cal-12T (pulmonary) ( 8 ) , H2009 (pulmonary) ( 13 ) , H2077 (pulmonary) ( 13 ) , H2887 (pulmonary) ( 13 ) , H322M (pulmonary) ( 13 ) , HCC2279 (pulmonary) ( 13 ) , HCC44 (pulmonary) ( 8 ) , HCC78 (pulmonary) ( 7 ) , HEK293T (epithelial) ( 23 ) , HeLa (cervical) ( 3 , 16 , 17 , 22 ) , HeLa S3 (cervical) ( 19 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 4 ) , HMLER ('stem, breast cancer') ( 4 ) , Jurkat (T lymphocyte) ( 9 ) , K562 (erythroid) ( 11 , 20 ) , LOU-NH91 (squamous) ( 13 ) , lung ( 5 , 6 , 7 , 8 ) , MDA-MB-231 (breast cell) ( 13 ) , NCI-H1299 (pulmonary) ( 6 ) , NCI-H1355 (pulmonary) ( 5 ) , NCI-H1395 (pulmonary) ( 13 ) , NCI-H1437 (pulmonary) ( 8 ) , NCI-H1666 (pulmonary) ( 8 ) , NCI-H1734 (pulmonary) ( 6 ) , NCI-H1781 (pulmonary) ( 7 ) , NCI-H1792 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 6 ) , NCI-H2030 (pulmonary) ( 13 ) , NCI-H2172 (pulmonary) ( 13 ) , NCI-H2228 (pulmonary) ( 7 ) , NCI-H23 (pulmonary) ( 5 ) , NCI-H2405 (pulmonary) ( 8 ) , NCI-H3122 (pulmonary) ( 7 , 10 ) , NCI-H3255 (pulmonary) ( 12 ) , NCI-H358 (pulmonary) ( 6 ) , NCI-H441 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 6 , 13 ) , NCI-H661 (pulmonary) ( 7 ) , WM239A (melanocyte) ( 2 )

Upstream Regulation
Treatments:	BI2536 ( 17 ) , MLN8054 ( 17 ) , nocodazole ( 19 ) , taxol ( 17 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
8	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
9	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
10	Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
11	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
12	Rikova K (2012) CST Curation Set: 16146; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
13	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
14	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
15	Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Curated Info
16	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
17	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
18	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
19	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
20	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
21	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
22	Zhou J (2008) CST Curation Set: 4842; Year: 2008; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993 Curated Info
23	Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6 17525332 Curated Info